118 patents
Utility
Solid State Form of Lemborexant
11 Jan 24
The present disclosure encompasses Lemborexant: succinic acid, a solid state form thereof, processes for preparation thereof, and pharmaceutical compositions thereof.
Zuzana Trcková, Adéla Bártová, Pavel Kolesa, Alexandr Jegorov
Filed: 10 Dec 20
Utility
Solid State Forms of Erdafitinib Salts and Processes for Preparation of Erdafitinib
11 Jan 24
The present disclosure relates to solid state forms of Erdafitinib salts, processes for preparation thereof, processes for preparation of Erdafitinib and pharmaceutical compositions thereof.
Zuzana Przeczkova, Adéla Bártová, Pavel Kolesa, Ondrej Skarka, Jirí Faustmann, Zdenek Horák, Zdenek Jelínek, Pavlína Horáková
Filed: 17 Aug 21
Utility
Rate-limited Syringe
21 Dec 23
The disclosure notably relates to a syringe.
Alexander Waldron, Jonathan Waller, James Irivn
Filed: 15 Nov 21
Utility
Solid State Forms of Pralsetinib and Process for Preparation Thereof
7 Dec 23
The present disclosure encompasses solid state forms of Pralsetinib and of Pralsetinib salts and co-crystals, in embodiments crystalline polymorphs of Pralsetinib, Pralsetinib salts and co-crystals processes for preparation thereof, and pharmaceutical compositions thereof.
Dijana Skalec Samec, Ivana Landeka
Filed: 19 Oct 21
Utility
Solid State Forms of Belumosudil and Belumosudil Salts
7 Dec 23
The present disclosure encompasses solid state forms of Belumosudil, in embodiments crystalline polymorphs of Belumosudil or salts thereof, processes for preparation thereof, and pharmaceutical compositions thereof.
Polina Lapido, Inbal Shumacher, Ofir Shaul
Filed: 22 Aug 23
Utility
Solid State Forms of Lumateperone Ditosylate Salt
30 Nov 23
Disclosed are solid state forms of lumateperone ditosylate, uses thereof, and pharmaceutical compositions thereof.
Ariel MITTELMAN, Ido FUCHS, Sharona SHACHANTOV, Doron RUDIK, Rotem SELLA-EREZ
Filed: 14 Aug 23
Utility
Solid State Forms of Lorecivivint
23 Nov 23
The present disclosure encompasses solid state forms of Lorecivivint, in embodiments crystalline polymorphs of Lorecivivint, processes for preparation thereof, and pharmaceutical compositions thereof.
Zuzana Przeczkova, Adéla Bártová, Pavel Kolesa, Alexandr Jegorov
Filed: 12 Oct 21
Utility
Solid State Forms of Trilaciclib and of Trilaciclib Salts
23 Nov 23
The present disclosure encompasses solid state forms of Trilaciclib and of Trilaciclib salts, in embodiments crystalline polymorphs of Trilaciclib and of Trilaciclib salts, processes for preparation thereof, and pharmaceutical compositions thereof.
Anantha Rajmohan Muthusamy, Amit Singh, Meenakshi Sundaram Somasundaram, Yogesh Dhananjay Wagh, Parven Kumar Luthra
Filed: 8 Oct 21
Utility
Solid State Forms of Resmetirom
16 Nov 23
The present disclosure encompasses solid state forms of Resmetirom, in embodiments crystalline polymorphs of Resmetirom, processes for preparation thereof, and pharmaceutical compositions thereof.
Polina Lapido, Jenny Goldshtein, Vitaly Krimer, Doron Rudik
Filed: 19 Oct 21
Utility
Solid State Forms of Gefapixant and Process for Preparation Thereof
9 Nov 23
The present disclosure encompasses solid state forms of Gefapixant, in embodiments crystalline polymorphs or salts or co-crystals of Gefapixant, processes for preparation thereof, and pharmaceutical compositions thereof.
Dijana Skalec Samec, Valentina Travancic
Filed: 16 Sep 21
Utility
Solid State Forms of SEP-363856 and Process for Preparation Thereof
26 Oct 23
Solid state forms of SEP-363856 HBr, SEP-363856 Fumarate, SEP-363856 R-camsylate and SEP-363856 S-camsylate and processes for preparation thereof, and pharmaceutical compositions thereof.
Polina Lapido, Limor Adani
Filed: 15 Sep 21
Utility
Solid State Forms of AT-001 and Process for Preparation Thereof
12 Oct 23
The present disclosure encompasses solid state forms of AT-001, in embodiments crystalline polymorphs of AT-001 or salts or co-crystals of AT-001, processes for preparation thereof, and pharmaceutical compositions thereof.
Anantha Rajmohan Muthusamy, Amit Singh, Yogesh Dhananjay Wagh
Filed: 7 Sep 21
Utility
Vial Adaptor with Valve
5 Oct 23
The invention relates to a vial adaptor.
Ivan Jurilj
Filed: 1 Sep 21
Utility
Solid State Forms of N-[2-(2-{4-[2-(6,7-DIMETHOXY-3,4-DIHYDRO-2(1H)-ISOQUINOLINYL)ETHYL]PHENYL}-2H-TETRAZOL-5-YL)-4,5-DIMETHOXYPHENYL]-4-OXO-4H-CHROMENE-2-CARBOXAMIDE Mesylate Salt
7 Sep 23
The present disclosure relates to solid state forms of Encequidar and Encequidar mesylate, processes for their preparation, and pharmaceutical compositions thereof.
Pavel Kolesa, Miroslav Vavrecka, Roman Gabriel, Martin Valík
Filed: 9 Jul 21
Utility
Solid State Forms of Avapritinib Salts
7 Sep 23
The present disclosure encompasses solid state forms of Avapritinib salts and co-crystals of the hydrochloride salt of Avapritinib, processes for preparation thereof, and pharmaceutical compositions thereof as well as their pharmaceutical use, in particular in the treatment of gastrointestinal stromal tumors (GIST), solid tumors and Advanced Systemic Mastocytosis.
Anantha Rajmohan Muthusamy, Yogesh Dhananjay Wagh, Siva Rama Krishna Muppalla, Parven Kumar Luthra, Meenakshi Sundaram Somasundaram
Filed: 15 Jun 21
Utility
Solid State Forms of Fezolinetant and Salts Thereof
31 Aug 23
The present disclosure encompasses solid state forms of Fezolinetant, including salts and cocrystals of Fezolinetant, in embodiments crystalline polymorphs of Fezolinetant, processes for preparation thereof, and pharmaceutical compositions thereof.
Helena Ceric, Nikolina Janton
Filed: 4 Aug 21
Utility
Treating Refractory Migraine
3 Aug 23
Disclosed herein are methods of treating or reducing incidence of migraine and/or at least one secondary symptom associated with refractory migraine in a subject having refractory migraine comprising administering to the subject a monoclonal antibody that modulates the CGRP pathway.
Marcelo Bigal, Ernesto Aycardi
Filed: 17 Feb 23
Utility
Antagonist Antibodies Directed Against Calcitonin Gene-Related Peptide and Methods Using Same
27 Jul 23
The invention features methods for preventing or treating CGRP associated disorders such as vasomotor symptoms and/or headaches (e.g., migraine, cluster headache, and tension headache) by administering an anti-CGRP antagonist antibody.
Marcelo Bigal, Sarah Walter, Henry Stern, Michael Chang
Filed: 12 Jul 22
Utility
Solid State Forms of Ensartinib and Ensartinib Salts
20 Jul 23
The present disclosure encompasses solid state forms and co-crystals of Ensartinib and of Ensartinib salts, in embodiments crystalline polymorphs of Ensartinib and of Ensartinib salts and co-crystals, processes for preparation thereof, and pharmaceutical compositions thereof.
Petar Bibulic, Sanja Matecic Musanic, Lorena Kordic
Filed: 3 Aug 21
Utility
Injection Spring for Aged Prefilled Syringe and Auto Injector
25 May 23
An auto injector apparatus includes a syringe and an auto injector.
Paul Andrew Christopher Gibson, Edward Andrew Cummings
Filed: 12 Dec 22